Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Unspecified VEGFR inhibitor|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Unspecified VEGFR inhibitor||VEGFR Inhibitor (Pan) 36|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 mutant||Advanced Solid Tumor||sensitive||Unspecified VEGFR inhibitor||Clinical Study - Cohort||Actionable||In a clinical study, VEGF/VEGFR inhibitor treatment resulted in improved rates of response (stable disease over 6 months/partial/complete response, 31% vs 7%), time-to-treatment failure, and overall survival (both p<0.01) compared to control in patients with TP53 mutant advanced solid tumors (n=106), but not in patients with TP53 wild-type tumors (n=82) (PMID: 27466356).||27466356|
|VHL mutant||renal cell carcinoma||no benefit||Unspecified VEGFR inhibitor||Clinical Study - Meta-analysis||Actionable||In a meta-analysis of 6 clinical studies, VHL mutation status was not associated with overall response rate (relative risk=1.47, p=0.20), progression-free survival (HR=1.02, p=0.91), or overall survival (HR=0.80, p=0.21) in a total of 633 patients with renal cell carcinoma who received anti-VEGF therapies (PMID: 28103578).||28103578|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|